ER+/HER2+ Metastatic Breast Cancer

1 Pogledi
administrator
administrator
07/03/23

Hope S. Rugo, MD, looks at the use of CDK4/6 inhibitors for patients with metastatic ER-positive, HER2-positive breast cancer and the trials evaluating their use in this setting.

  • Kategorija

Prikaži više

0 Komentari Poredaj po

Nema komentara

Komentari na Facebooku

Sljedeći